The Democratic Republic of Congo is experiencing the second-largest Ebola outbreak in history, with cases reaching 9,066 and deaths totaling 4,381. This outbreak is caused by the Bundibugyo strain of the virus, which differs from the Zaire strain that triggered the 2014-2016 West Africa outbreak that killed more than 11,000 people. The current outbreak has a case-fatality rate of 48.2%, and the Bundibugyo strain currently lacks approved treatments or vaccines.
In response to the outbreak, CEPI announced plans for a phase 2/3 trial called Tumaini to evaluate vaccine candidates against the Bundibugyo virus. The adaptive platform trial will test multiple vaccine candidates simultaneously, including Ervebo and at least two Bundibugyo-specific candidates. Meanwhile, the Bravo study, coordinated by Doctors Without Borders, is already evaluating the Ervebo vaccine’s effectiveness against the Bundibugyo strain in North Kivu and Ituri province, where 857 frontline workers have been vaccinated.
Source: Read the full story at CIDRAP
This summary was written with AI assistance from the linked source.
Send this to yourself, or to someone who should see it
Enter your email and we will send you a link to this article.
